Summary
Merck KGaA (Merck) is a pharmaceutical and chemical company, which operates its business in three markets namely, healthcare market, performance materials market and life sciences market. Its business operations include promoting prescription drugs of chemical and biological origin and over-the-counter products for preventive health care and the self-treatment of minor ailments (healthcare market); identifying, developing and manufacturing biotech and pharmaceutical drugs and general laboratory applications (life sciences market); and developing liquid crystal mixtures and cosmetic active ingredients (performance materials market). The company has operations in over 66 countries spread across Europe, North America, South America, Africa, Asia and Australia. It is a subsidiary of E. Merck KG and is headquartered in Darmstadt, Germany.
Merck KGaA (MRK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 12
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 13
Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 14
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 15
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 16
Merck KGaA, Medical Devices Deals, 2010 to YTD 2016 18
Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 19
Merck KGaA, Pharmaceuticals & Healthcare, Deal Details 32
Asset Purchase 32
Merck KgaA Acquires SevenSeas Original Brand 32
Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 33
Venture Financing 34
Asceneuron Raises USD30.6 Million in Series A Financing 34
TocopheRx Raises US$3.3 Million In Seed Financing 36
Calypso Biotech To Raise US$3.2 Million In Seed Financing 37
Asceneuron Raises US$6.4 Million In Seed Financing 38
VAXIMM Secures US$8 Million In Venture Financing 39
Private Equity 41
Merck Sells Its Pharma Operations To Nkunzi Investment And Omame 41
Partnerships 42
Merck Enters Into Licensing Agreement With BeiGene For BeiGene-290 42
Proteome Sciences Enters Into License Agreement With Sigma-Aldrich 43
Selvita Enters into Agreement with Merck 44
Merck Enters into Agreement with University of Buea 45
Merck, Pfizer and Verastem Enter into Agreement 46
Merck Enters into Research Agreement with European Molecular Biology Labs 47
Merck, Pfizer and Syndax Pharma Enter into Agreement 48
Selvita Enters into Development and Commercialization Agreement with Merck 49
Biothera Pharma Enters into Partnership with Merck 50
Sigma-Aldrich Enters into Agreement with Sanger Institute 51
Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 52
Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 53
Aeterna Zentaris Enters into Agreement with EMD Serono 54
Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 55
Lucigen Enters into Distribution Agreement with Sigma-Aldrich 56
Merck Serono Enters into Co-Development Agreement with MMV 57
Sigma-Aldrich Enters into Distribution Agreement with Roche 58
Merck Serono Terminates Agreement with Bristol-Myers Squibb 59
Merck Enters into Development Agreement with Precision Biologics 61
Pfizer Enters into Co-Development Agreement with Merck 62
BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 64
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 65
Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 66
Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 67
Lupin Enters into Co-Development Agreement with Merck Serono 68
Merck Serono Extends R&D Agreement with San Raffaele 69
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 70
Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 71
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 72
EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 74
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 75
Biopharm Enters Into Research Agreement With Merck Serono 76
Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 77
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 79
Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 80
Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 81
Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 83
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 84
Fusion Antibodies Enters into Agreement with Calypso Biotech 86
Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 87
Isu Abxis Enters into Co-Development Agreement with Merck 88
Luminex Extends Distribution Agreement With EMD Millipore 89
Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 90
Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 92
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 93
Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 94
Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 96
EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 97
AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 98
EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 99
Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 100
Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 101
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 102
TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 103
Genovis Enters Into Distribution Agreement With Sigma-Aldrich 104
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 105
EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 107
EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 108
Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 109
Mapi Pharma Amends Co-Development Agreement with Merck 111
TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 112
Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 113
IntelliCell BioSciences Enters Into Co-Marketing Agreement With Millipore 115
f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 116
Emmaus Medical Terminates Co-Promotion Agreement With EMD Serono For Zorbtive 117
BASF Enters Into Distribution Agreement With Sigma-Aldrich 118
Lead Discovery Center Enters Into Agreement With Merck Serono 119
Merck Serono Enters Into Research Agreement With Philochem 120
Merck Serono Enters Into Co-Development Agreement With Sanofi-aventis 121
EMD Serono Enters Into Co-Marketing Agreement With Tercica 122
Merck Serono Extends Co-Development Agreement With INSpe And Department Of Neurology Of San Raffaele 123
Evotec Enters Into Collaboration With Merck KGaA 124
Domainex Enters Into Collaboration With Sigma-Aldrich 125
Sigma Life Science Enters Into Co-Marketing Agreement With JAX 126
Sigma Life Science Enters Into An Agreement With Autism Speaks 127
Ablynx Enters Into Second Co-Discovery And Co-Development Agreement With Merck Serono 128
EDELRIS Enters Into Collaboration With Merck Serono 129
Generex Biotech Enters Into Co-Marketing Agreement With Merck 130
Sigma Life Science Enters Into An Agreement With SwitchGear 131
Millipore Enters Into Collaboration With BioOutsource 132
Sigma-Aldrich Enters Into Distribution Agreement With New Mexico Highlands 133
Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim 134
Swedish Orphan Biovitrum Expands Distribution Agreement With Merck Serono 135
Eden Biodesign Enters Into A Collaboration With Millipore 136
Sigma-Aldrich Enters Into Commercialization Agreement With Pfizer 137
Sigma-Aldrich Enters Into Distribution Agreement With Eka Chemicals 138
BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono 139
Cancer Research And Cancer Research Technology Enter Into An Agreement With Merck 140
Licensing Agreements 141
Merck Enters into Licensing Agreement with Weizmann Institute of Science 141
Merck Serono Terminates its Licensing Agreement with BioMarin Pharma 142
Relief Therapeutics Enters into Licensing Agreement with Merck Serono 143
EMD Millipore Enters into Licensing Agreement with Singulex 144
Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 145
Intrexon Enters into Licensing Agreement with Merck Serono 146
Symphogen Terminates Licensing Agreement with Merck for Anticancer Candidate Sym004 147
Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 149
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 150
Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 152
EMD Serono Enters into Licensing Agreement with Mersana Therapeutics 154
Merck Serono Terminates Licensing Agreement with Ono Pharma for ONO-4641 155
MorphoSys Enters into Licensing Agreement with Merck Serono 156
Theratechnologies Terminates Collaboration And Licensing Agreement With EMD Serono For Tesamorelin 157
Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 159
Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 161
Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 162
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 163
ObsEva Enters Into Licensing Agreement With Merck Serono 164
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 165
Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 167
Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 169
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 170
Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 171
Calypso Biotech Enters Into Licensing Agreement With iDD Biotech 172
Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 173
Merck Serono Amends Option and Licensing Agreement with Opexa Therapeutics 175
Merck Serono Terminates Licensing Agreement With Flamel Technologies 177
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 178
EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 179
Materia Extends Licensing Agreement With Sigma Aldrich 180
Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 181
PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 182
Bionomics Terminates Licensing Agreement With Merck Serono 183
Ligand Pharma Enters Into Licencing Agreement With Merck 184
Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 185
EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 186
Sigma Life Science Enters Into Licensing Agreement With Kyoto University 187
Idera Pharma Terminates Licensing Agreement With Merck 188
Merck Serono Terminates Its Licensing Agreement With Newron For Safinamide 190
Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 192
Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 194
WntResearch Enters into Licensing Agreement with EMD Millipore 196
Affectis Pharma Enters Into Licensing Agreement With Merck Serono 197
Sigma Life Science Enters Into Licensing Agreement With King's College London 199
Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 200
Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 202
Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 203
Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin 205
Recordati Enters Into Licensing Agreement With Merck For Cardicor 206
Sanofi-aventis Enters Into Licensing Agreement With Merck Serono For AS703026 207
Merck Serono Enters Into Licensing Agreement With Sanofi-aventis For XL765 209
Plasticell Enters Into Licensing Agreement With Sigma-Aldrich 210
Millipore Enters into Licensing Agreement with Wayne State University 211
Allozyne Enters Into Licensing Agreement With Sigma-Aldrich 212
PregLem Enters Into Licensing Agreement With Merck Serono 213
University Of Illinois At Urbana-Champaign Enters Into Licensing Agreement With Sigma-Aldrich 214
EMD Millipore Enters Into Licensing Agreement With The Cleveland Clinic 215
Immunovaccine Enters Into License Agreement With Merck 216
Merck Serono Expands Licensing Agreement With Bionomics 217
Columbia Labs Renews Licensing Agreement With Merck Serono 218
Merck Terminates Worldwide Licensing Agreement With Lpath 219
Sigma-Aldrich Enters Into Licensing Agreement With CSIRO 220
Flexion Therapeutics Enters Into Licensing Agreement With Four Pharma Companies 221
Debt Offering 223
Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 223
Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 224
Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 225
Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 226
Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 227
Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 228
Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 229
Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 230
Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 231
Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 232
Sigma-Aldrich Completes An Underwritten Public Offering Of Senior Notes Due 2020 For US$300 Million 233
Asset Transactions 235
Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 235
Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 237
Eurofins Scientific To Acquire Assets Of Discovery And Development Solutions Business Of Merck 238
Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 239
Noreva Pharma Acquires Dermo-Cosmetic Brands From Merck Medication 240
Acquisition 241
Merck Sells Bangalore Genei for USD1.5 Million 241
Merck May Sell Allergopharma for up to USD638 Million 242
Merck Acquires Sigma-Aldrich for USD17 Billion 243
Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 246
Merck And BASF Acquire Majority Stake In Innovation Lab 247
Albany Molecular Research Completes Acquisition Of Cedarburg Pharma For US$41 Million 248
EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 250
Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 251
Proxy Labs Acquires MicroSafe Laboratories From Millipore 252
Sigma-Aldrich Completes Acquisition Of BioReliance For US$350 Million 253
Sigma-Aldrich Acquires Vetec Quimica Fina 255
CAPS Holdings Terminates Acquisition Of Merck (Pty) 256
Sigma-Aldrich Acquires Resource Technology 257
Teva Pharma Industries Acquires THERAMEX From Merck Serono 258
Merck Acquires Beijing Skywing Technology For US$18.2 Million 260
Sigma-Aldrich Acquires Cerilliant From Argenta Partners 261
Merck Completes Acquisition Of Millipore 263
Sigma-Aldrich Acquires Ace Animals 266
BioReliance Acquires CynerGene 267
Merck KGaA - Key Competitors 268
Key Employees 269
Locations And Subsidiaries 270
Head Office 270
Other Locations & Subsidiaries 270
Appendix 280
Methodology 280
About GlobalData 280
Contact Us 280
Disclaimer 280
List of Tables
Merck KGaA, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 13
Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 14
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 15
Merck KGaA, Deals By Therapy Area, 2010 to YTD 2016 16
Merck KGaA, Medical Devices Deals, 2010 to YTD 2016 18
Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 19
Merck KgaA Acquires SevenSeas Original Brand 32
Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 33
Asceneuron Raises USD30.6 Million in Series A Financing 34
TocopheRx Raises US$3.3 Million In Seed Financing 36
Calypso Biotech To Raise US$3.2 Million In Seed Financing 37
Asceneuron Raises US$6.4 Million In Seed Financing 38
VAXIMM Secures US$8 Million In Venture Financing 39
Merck Sells Its Pharma Operations To Nkunzi Investment And Omame 41
Merck Enters Into Licensing Agreement With BeiGene For BeiGene-290 42
Proteome Sciences Enters Into License Agreement With Sigma-Aldrich 43
Selvita Enters into Agreement with Merck 44
Merck Enters into Agreement with University of Buea 45
Merck, Pfizer and Verastem Enter into Agreement 46
Merck Enters into Research Agreement with European Molecular Biology Labs 47
Merck, Pfizer and Syndax Pharma Enter into Agreement 48
Selvita Enters into Development and Commercialization Agreement with Merck 49
Biothera Pharma Enters into Partnership with Merck 50
Sigma-Aldrich Enters into Agreement with Sanger Institute 51
Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 52
Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 53
Aeterna Zentaris Enters into Agreement with EMD Serono 54
Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 55
Lucigen Enters into Distribution Agreement with Sigma-Aldrich 56
Merck Serono Enters into Co-Development Agreement with MMV 57
Sigma-Aldrich Enters into Distribution Agreement with Roche 58
Merck Serono Terminates Agreement with Bristol-Myers Squibb 59
Merck Enters into Development Agreement with Precision Biologics 61
Pfizer Enters into Co-Development Agreement with Merck 62
BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 64
Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 65
Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 66
Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 67
Lupin Enters into Co-Development Agreement with Merck Serono 68
Merck Serono Extends R&D Agreement with San Raffaele 69
Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 70
Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 71
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 72
EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 74
KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 75
Biopharm Enters Into Research Agreement With Merck Serono 76
Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 77
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 79
Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 80
Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 81
Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 83
Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 84
Fusion Antibodies Enters into Agreement with Calypso Biotech 86
Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 87
Isu Abxis Enters into Co-Development Agreement with Merck 88
Luminex Extends Distribution Agreement With EMD Millipore 89
Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 90
Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 92
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 93
Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 94
Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 96
EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 97
AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 98
EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 99
Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 100
Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 101
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 102
TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 103
Genovis Enters Into Distribution Agreement With Sigma-Aldrich 104
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 105
EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 107
EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 108
Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 109
Mapi Pharma Amends Co-Development Agreement with Merck 111
TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 112
Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 113
IntelliCell BioSciences Enters Into Co-Marketing Agreement With Millipore 115
f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 116
Emmaus Medical Terminates Co-Promotion Agreement With EMD Serono For Zorbtive 117
BASF Enters Into Distribution Agreement With Sigma-Aldrich 118
Lead Discovery Center Enters Into Agreement With Merck Serono 119
Merck Serono Enters Into Research Agreement With Philochem 120
Merck Serono Enters Into Co-Development Agreement With Sanofi-aventis 121
EMD Serono Enters Into Co-Marketing Agreement With Tercica 122
Merck Serono Extends Co-Development Agreement With INSpe And Department Of Neurology Of San Raffaele 123
Evotec Enters Into Collaboration With Merck KGaA 124
Domainex Enters Into Collaboration With Sigma-Aldrich 125
Sigma Life Science Enters Into Co-Marketing Agreement With JAX 126
Sigma Life Science Enters Into An Agreement With Autism Speaks 127
Ablynx Enters Into Second Co-Discovery And Co-Development Agreement With Merck Serono 128
EDELRIS Enters Into Collaboration With Merck Serono 129
Generex Biotech Enters Into Co-Marketing Agreement With Merck 130
Sigma Life Science Enters Into An Agreement With SwitchGear 131
Millipore Enters Into Collaboration With BioOutsource 132
Sigma-Aldrich Enters Into Distribution Agreement With New Mexico Highlands 133
Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim 134
Swedish Orphan Biovitrum Expands Distribution Agreement With Merck Serono 135
Eden Biodesign Enters Into A Collaboration With Millipore 136
Sigma-Aldrich Enters Into Commercialization Agreement With Pfizer 137
Sigma-Aldrich Enters Into Distribution Agreement With Eka Chemicals 138
BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono 139
Cancer Research And Cancer Research Technology Enter Into An Agreement With Merck 140
Merck Enters into Licensing Agreement with Weizmann Institute of Science 141
Merck Serono Terminates its Licensing Agreement with BioMarin Pharma 142
Relief Therapeutics Enters into Licensing Agreement with Merck Serono 143
EMD Millipore Enters into Licensing Agreement with Singulex 144
Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 145
Intrexon Enters into Licensing Agreement with Merck Serono 146
Symphogen Terminates Licensing Agreement with Merck for Anticancer Candidate Sym004 147
Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 149
EMD Serono Enters into Licensing Agreement with Sutro Biopharma 150
Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 152
EMD Serono Enters into Licensing Agreement with Mersana Therapeutics 154
Merck Serono Terminates Licensing Agreement with Ono Pharma for ONO-4641 155
MorphoSys Enters into Licensing Agreement with Merck Serono 156
Theratechnologies Terminates Collaboration And Licensing Agreement With EMD Serono For Tesamorelin 157
Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 159
Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 161
Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 162
Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 163
ObsEva Enters Into Licensing Agreement With Merck Serono 164
Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 165
Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 167
Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 169
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 170
Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 171
Calypso Biotech Enters Into Licensing Agreement With iDD Biotech 172
Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 173
Merck Serono Amends Option and Licensing Agreement with Opexa Therapeutics 175
Merck Serono Terminates Licensing Agreement With Flamel Technologies 177
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 178
EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 179
Materia Extends Licensing Agreement With Sigma Aldrich 180
Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 181
PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 182
Bionomics Terminates Licensing Agreement With Merck Serono 183
Ligand Pharma Enters Into Licencing Agreement With Merck 184
Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 185
EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 186
Sigma Life Science Enters Into Licensing Agreement With Kyoto University 187
Idera Pharma Terminates Licensing Agreement With Merck 188
Merck Serono Terminates Its Licensing Agreement With Newron For Safinamide 190
Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 192
Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 194
WntResearch Enters into Licensing Agreement with EMD Millipore 196
Affectis Pharma Enters Into Licensing Agreement With Merck Serono 197
Sigma Life Science Enters Into Licensing Agreement With King's College London 199
Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 200
Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 202
Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 203
Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin 205
Recordati Enters Into Licensing Agreement With Merck For Cardicor 206
Sanofi-aventis Enters Into Licensing Agreement With Merck Serono For AS703026 207
Merck Serono Enters Into Licensing Agreement With Sanofi-aventis For XL765 209
Plasticell Enters Into Licensing Agreement With Sigma-Aldrich 210
Millipore Enters into Licensing Agreement with Wayne State University 211
Allozyne Enters Into Licensing Agreement With Sigma-Aldrich 212
PregLem Enters Into Licensing Agreement With Merck Serono 213
University Of Illinois At Urbana-Champaign Enters Into Licensing Agreement With Sigma-Aldrich 214
EMD Millipore Enters Into Licensing Agreement With The Cleveland Clinic 215
Immunovaccine Enters Into License Agreement With Merck 216
Merck Serono Expands Licensing Agreement With Bionomics 217
Columbia Labs Renews Licensing Agreement With Merck Serono 218
Merck Terminates Worldwide Licensing Agreement With Lpath 219
Sigma-Aldrich Enters Into Licensing Agreement With CSIRO 220
Flexion Therapeutics Enters Into Licensing Agreement With Four Pharma Companies 221
Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 223
Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 224
Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 225
Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 226
Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 227
Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 228
Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 229
Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 230
Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 231
Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 232
Sigma-Aldrich Completes An Underwritten Public Offering Of Senior Notes Due 2020 For US$300 Million 233
Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 235
Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 237
Eurofins Scientific To Acquire Assets Of Discovery And Development Solutions Business Of Merck 238
Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 239
Noreva Pharma Acquires Dermo-Cosmetic Brands From Merck Medication 240
Merck Sells Bangalore Genei for USD1.5 Million 241
Merck May Sell Allergopharma for up to USD638 Million 242
Merck Acquires Sigma-Aldrich for USD17 Billion 243
Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 246
Merck And BASF Acquire Majority Stake In Innovation Lab 247
Albany Molecular Research Completes Acquisition Of Cedarburg Pharma For US$41 Million 248
EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 250
Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 251
Proxy Labs Acquires MicroSafe Laboratories From Millipore 252
Sigma-Aldrich Completes Acquisition Of BioReliance For US$350 Million 253
Sigma-Aldrich Acquires Vetec Quimica Fina 255
CAPS Holdings Terminates Acquisition Of Merck (Pty) 256
Sigma-Aldrich Acquires Resource Technology 257
Teva Pharma Industries Acquires THERAMEX From Merck Serono 258
Merck Acquires Beijing Skywing Technology For US$18.2 Million 260
Sigma-Aldrich Acquires Cerilliant From Argenta Partners 261
Merck Completes Acquisition Of Millipore 263
Sigma-Aldrich Acquires Ace Animals 266
BioReliance Acquires CynerGene 267
Merck KGaA, Key Competitors 268
Merck KGaA, Key Employees 269
Merck KGaA, Subsidiaries 270
List of Figures
Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Merck KGaA
